Consensus Alvotech

Stocks

ALVO

LU2458332611

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:47:23 2026-06-18 EDT			5-day change	1st Jan Change
3.855 ^USD	-9.08%		+2.42%	-17.35%

07:38am	Alvotech Completes $165 Million Equity Raise	MT
06:47am	Alvotech Closes $98 Million Share Offering	MT

Evolution of the Average Target: Alvotech

Evolution of the Target Price: Alvotech

Changes in Analyst Recommendations: Alvotech

17cedb11d4b3842f23b.sspgb8zVz0IAzqa2iraTFeyO2A8a-k0AM8S7eytpzn0.i_ITKLWZliA5987X2PXwYsG-uWVzvChJAJ3yQ24AgQnVricgv7-BBmKRng~a33bf67da57d0ada53a3228f91aa68e8

Analysts' recommendations: Alvotech

03-24	UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating	MT
03-24	Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating	MT
12-22	Stockholm Bullets - Viscaria Soars on Buy Recommendation	FW
11-18	UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating	MT
11-04	Alvotech Shares Fall After Deutsche Bank Downgrade	MT
11-04	Deutsche Bank Downgrades Alvotech to Hold From Buy, Adjusts Price Target to $8 From $14	MT
11-04	Deutsche Bank Downgrades Alvotech to Hold From Buy, Cuts Price Target to $8 From $14	MT
11-03	Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar	DJ
11-03	Top Premarket Decliners	MT
11-03	Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell	MT
11-02	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05	CI
25-10-14	Alvotech Shares Rise After Morgan Stanley Upgrade	MT
25-10-14	Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14	MT
25-09-23	Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says	MT
25-09-23	Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14	MT
25-07-21	UBS Says Alvotech Set for H2 Growth on Pipeline Launches, Private Label Deal	MT
25-07-18	UBS Adjusts Price Target on Alvotech to $14 From $16, Maintains Buy Rating	MT
24-07-25	Barclays Adjusts Price Target on Alvotech to $18 From $22, Maintains Overweight Rating	MT
24-05-24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
24-03-22	Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	MT
24-01-29	Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10	MT
23-10-20	Citigroup Upgrades Alvotech to Neutral From Sell, Adjusts Price Target to $10 From $5	MT
23-09-21	Barclays Initiates Alvotech With Equalweight Rating, Price Target is $10	MT
23-06-30	Deutsche Bank Adjusts Alvotech Price Target to $8 From $12, Maintains Hold Rating	MT
23-03-07	Deutsche Bank Adjusts Alvotech's Price Target to $12 From $8, Maintains Hold Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALVOTECH					+253.34%
	LONZA GROUP AG					+34.51%
	REVOLUTION MEDICINES, INC.					+18.71%
	IQVIA HOLDINGS INC.					+32.2%
	BEONE MEDICINES AG					+56.98%
	CELLTRION, INC.					+45.19%
	MEDPACE HOLDINGS, INC.					-3.12%
	EUROFINS SCIENTIFIC SE					+13.34%
	IONIS PHARMACEUTICALS, INC.					+40.71%
	Average					+54.65%
	Weighted average by Cap.					+34.08%